Anixa Biosciences ANIX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.06 (+1.99%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Anixa Biosciences (ANIX)
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.84

  • Market Cap

    $91.44 Million

  • Price-Earnings Ratio

    -7.28

  • Total Outstanding Shares

    32.20 Million Shares

  • Total Employees

    5

  • Dividend

    No dividend

  • IPO Date

    April 12, 1989

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    3150 almaden expressway, suite 250, San jose, CA, 95118

  • Homepage

    https://www.anixa.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

November 1, 2023 to October 31, 2024
MetricValue
Net Cash Flow, Continuing$356,000
Net Cash Flow From Investing Activities, Continuing$4.28 Million
Net Cash Flow From Financing Activities$3.42 Million
Net Cash Flow From Operating Activities$-7.33 Million
Net Cash Flow$356,000
Net Cash Flow From Operating Activities, Continuing$-7.33 Million

Income Statement

November 1, 2023 to October 31, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Basic Average Shares$31,898
Net Income/Loss Attributable To Noncontrolling Interest$-144,000
Operating Income/Loss$-13.83 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Costs And Expenses$13.83 Million

Comprehensive Income

November 1, 2023 to October 31, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-12.70 Million
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss$-12.70 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

November 1, 2023 to October 31, 2024
MetricValue
Assets$21.59 Million
Current Liabilities$2.50 Million
Liabilities And Equity$21.59 Million
Current Assets$21.36 Million
Accounts Receivable$173,000
Noncurrent Liabilities$203,000

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ANIX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.